These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 16614849)

  • 41. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
    Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
    Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
    Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
    J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
    Sovak MA; Lutzker S; Zheng L; Guensch L; Joyce M; Schwartz S; Wu Y; Aisner J
    Lung Cancer; 2006 Aug; 53(2):177-81. PubMed ID: 16790293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
    Georgoulias V; Kouroussis C; Androulakis N; Kakolyris S; Dimopoulos MA; Papadakis E; Bouros D; Apostolopoulou F; Papadimitriou C; Agelidou A; Hatzakis K; Kalbakis K; Kotsakis A; Vardakis N; Vlachonicolis J
    J Clin Oncol; 1999 Mar; 17(3):914-20. PubMed ID: 10071284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
    Favaretto A; Ceresoli GL; Paccagnella A; Barbieri F; Bearz A; Ghiotto C; Oniga F; Schiavon S; Frustaci S; Villa E
    Ann Oncol; 2000 Nov; 11(11):1421-6. PubMed ID: 11142482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
    Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
    Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
    Shi X; Yu XM; Zhang YP; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
    Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
    Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
    Usami N; Yokoi K; Hasegawa Y; Taniguchi H; Shindo J; Yamamoto M; Suzuki R; Imaizumi K; Kondo M; Shimokata K;
    Int J Clin Oncol; 2010 Dec; 15(6):583-7. PubMed ID: 20714770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
    Langer C; Li S; Schiller J; Tester W; Rapoport BL; Johnson DH;
    J Clin Oncol; 2007 Feb; 25(4):418-23. PubMed ID: 17264337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
    Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
    J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
    Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
    Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.